Related Experiment Video

Updated: Apr 30, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K

New developments in the treatment of castration resistant prostate cancer

Roxanne Wadia, Daniel P Petrylak1

  • 1Department of Medicine, Smilow Cancer Center, Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, Connecticut, USA.

Asian Journal of Andrology
|April 25, 2014
PubMed

Insights

Recent advances significantly improve metastatic castrate-resistant prostate cancer (CRPC) treatment. New drugs and genetic insights offer better diagnosis and prediction for this complex disease.

Area of Science:

  • Oncology
  • Urology
  • Cancer Research

Background:

  • Metastatic castrate-resistant prostate cancer (CRPC) remains a significant clinical challenge.
  • Recent years have seen dramatic improvements in understanding and treating CRPC.

Purpose of the Study:

  • To summarize recent advances in CRPC.
  • To highlight new therapeutic targets and drugs.
  • To discuss the role of genetic mutations in CRPC.

Main Methods:

  • Review of recent scientific literature.
  • Analysis of emerging treatment strategies.
  • Exploration of the mechanisms of castration resistance.

Main Results:

  • Significant progress in understanding CRPC development.
  • Identification of novel drug targets.
  • Development of new therapeutic agents.

Conclusions:

  • Advances in basic research have led to improved CRPC treatments.
  • Genetic insights promise more accurate diagnosis and prognosis.
  • The landscape of CRPC management is rapidly evolving.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K
Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

46.8K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K